These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 19578775

  • 1. Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: a phase II study.
    Stathopoulos GP, Koutantos J, Vaslamatzis MM, Athanasiadis A, Papadopoulos G, Labrodimou G, Stathopoulos J, Rigatos S.
    Oncol Rep; 2009 Aug; 22(2):345-8. PubMed ID: 19578775
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
    Amato RJ, Hernandez-McClain J, Henary H.
    Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
    Borden LS, Clark PE, Lovato J, Hall MC, Stindt D, Harmon M, M Mohler R, Torti FM.
    Cancer; 2006 Sep 01; 107(5):1093-100. PubMed ID: 16888761
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.
    Amin A, Halabi S, Gelmann EP, Stadler W, Vogelzang N, Small E.
    Urol Oncol; 2004 Sep 01; 22(5):398-403. PubMed ID: 15464920
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.
    Eur Urol; 2009 May 01; 55(5):1112-23. PubMed ID: 19042080
    [Abstract] [Full Text] [Related]

  • 19. The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
    Samelis GF, Kalofonos H, Adamou A, Kosmides P, Skarlos D, Aravantinos G, Kiamouris C, Adimchi O, Fountzilas G, Dimopoulos AM.
    Urology; 2005 Aug 01; 66(2):382-5. PubMed ID: 16098366
    [Abstract] [Full Text] [Related]

  • 20. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
    Numata K, Miura N, Azuma K, Karashima T, Kasahara K, Nakatsuzi H, Hashine K, Sumiyoshi Y.
    Hinyokika Kiyo; 2007 Feb 01; 53(2):99-104. PubMed ID: 17352158
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.